日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Plasminogen Activator Inhibitor-1 Mediates Tolerance to Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer.

纤溶酶原激活物抑制剂-1介导非小细胞肺癌对PD-1抗免疫疗法的耐受性。

Sumii Masahiko, Masuda Takeshi, Shimoji Kiyofumi, Yamaguchi Kakuhiro, Sakamoto Shinjiro, Horimasu Yasushi, Mimae Takahiro, Nakashima Taku, Iwamoto Hiroshi, Miyata Yoshihiro, Hamada Hironobu, Okada Morihito, Miyata Toshio, Hattori Noboru

Overview: PAI-1 inhibitors and clinical applications

概述:PAI-1抑制剂及其临床应用

Miyata, Toshio

PAI-1 is a common driver of aging and diverse diseases

PAI-1是衰老和多种疾病的常见驱动因素。

Khoddam, Alireza; Miyata, Toshio; Vaughan, Douglas

Plasminogen activator inhibitor 1 promotes aortic aging-like pathophysiology in humans and mice

纤溶酶原激活物抑制剂 1 可促进人类和小鼠的主动脉衰老样病理生理变化

Khoddam, Alireza; Kalousdian, Anthony; Eren, Mesut; Soberanes, Saul; Decker, Andrew; Lux, Elizabeth J; Zywicki, Benjamin W; Dinh, Brian; Boztepe, Bedirhan; Cheema, Baljash S; Cuda, Carla M; Abdala-Valencia, Hiam; Sivakumar, Arun; Miyata, Toshio; Wilsbacher, Lisa D; Vaughan, Douglas E

Lactococcus lactis strain Plasma activates plasmacytoid dendritic cells and mitigates common cold-like symptoms in healthy adults: a meta-analysis of individual participant data

乳酸乳球菌Plasma菌株可激活浆细胞样树突状细胞并减轻健康成人的普通感冒样症状:一项基于个体参与者数据的荟萃分析

Kato, Yukiko; Kobayashi, Keiko; Kuramochi, Yui; Miyata, Toshio; Ushida, Yusuke; Hayamizu, Kohsuke

Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials

日本药物滞后和药物流失评估:参与全球III期肿瘤试验

Shiga, Kaname; Shibata, Taro; Miyata, Toshio

Pyridoxamine does not reduce arterial stiffness in an 8-week randomized double-blind placebo-controlled intervention trial with abdominally obese individuals

一项针对腹型肥胖人群的为期 8 周的随机双盲安慰剂对照干预试验表明,吡哆胺并不能降低动脉僵硬度。

Van den Eynde, Mathias D G; van der Bruggen, Myrthe M; Houben, Alfons J H M; Reesink, Koen D; Spronck, Bart; Delhaas, Tammo; Scheijen, Jean J L J M; Miyata, Toshio; Schalkwijk, Casper G

A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19

一项针对轻度至中度 COVID-19 患者的纤溶酶原激活物抑制剂-1 (TM5614) 的随机双盲安慰剂对照试验

Hirai, Toyohiro; Asano, Koichiro; Ito, Isao; Miyazaki, Yasunari; Sugiura, Hisatoshi; Agirbasli, Mehmet; Kobayashi, Seiichi; Kobayashi, Makoto; Shimada, Daishi; Natsume, Ichiro; Kawasaki, Tsutomu; Ohba, Takehiko; Tajiri, Sakurako; Sakamaki, Fumio; Mineshita, Masamichi; Takihara, Takahisa; Sekiya, Kiyoshi; Tomii, Keisuke; Tomioka, Hiromi; Kita, Hideo; Nishizaka, Yasuo; Fukui, Motonari; Miyata, Toshio; Harigae, Hideo

A PAI-1 antagonist ameliorates hypophosphatemia in the Hyp vitamin D-resistant rickets model mouse.

PAI-1 拮抗剂可改善 Hyp 维生素 D 抵抗性佝偻病模型小鼠的低磷血症

Qian Cheng, Ito Nobuaki, Tsuji Kunikazu, Sato Shingo, Kikuchi Katsushi, Yoshii Toshitaka, Miyata Toshio, Asou Yoshinori

Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer

治疗原理和方案设计:一项研究者发起的II期临床研究,旨在评估纳武利尤单抗联合PAI-1抑制剂TM5614治疗既往接受过治疗的非小细胞肺癌患者的疗效。

Masuda, Takeshi; Hirata, Taizo; Sakamoto, Tomohiro; Tsubata, Yukari; Ichihara, Eiki; Kozuki, Toshiyuki; Shoda, Hiroyasu; Motonaga, Masanori; Yoshida, Takako; Fukutani, Miki; Tsuji-Takayama, Kazue; Tamura, Atsushi; Amagase, Harunobu; Fujihara, Hideki; Aoki, Gaku; Akita, Tomoyuki; Orihashi, Yasushi; Miyata, Toshio; Hattori, Noboru